- Home
- SNTI vs NYC Comparison
SNTI vs NYC Comparison
Compare SNTI & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- NYC
- Stock Information
- Founded
- SNTI 2016
- NYC 2013
- Country
- SNTI United States
- NYC United States
- Employees
- SNTI N/A
- NYC N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- SNTI Health Care
- NYC Finance
- Exchange
- SNTI Nasdaq
- NYC Nasdaq
- Market Cap
- SNTI 50.3M
- NYC 40.9M
- IPO Year
- SNTI N/A
- NYC N/A
- Fundamental
- Price
- SNTI $1.70
- NYC $13.11
- Analyst Decision
- SNTI Strong Buy
- NYC
- Analyst Count
- SNTI 2
- NYC 0
- Target Price
- SNTI $8.50
- NYC N/A
- AVG Volume (30 Days)
- SNTI 511.1K
- NYC 3.4K
- Earning Date
- SNTI 08-12-2025
- NYC 08-08-2025
- Dividend Yield
- SNTI N/A
- NYC N/A
- EPS Growth
- SNTI N/A
- NYC N/A
- EPS
- SNTI N/A
- NYC N/A
- Revenue
- SNTI N/A
- NYC $58,397,000.00
- Revenue This Year
- SNTI N/A
- NYC $8.40
- Revenue Next Year
- SNTI $150.00
- NYC $1.62
- P/E Ratio
- SNTI N/A
- NYC N/A
- Revenue Growth
- SNTI N/A
- NYC N/A
- 52 Week Low
- SNTI $1.52
- NYC $7.89
- 52 Week High
- SNTI $16.94
- NYC $16.30
- Technical
- Relative Strength Index (RSI)
- SNTI 29.96
- NYC 46.86
- Support Level
- SNTI $1.86
- NYC $11.90
- Resistance Level
- SNTI $2.12
- NYC $14.73
- Average True Range (ATR)
- SNTI 0.15
- NYC 0.81
- MACD
- SNTI 0.00
- NYC -0.28
- Stochastic Oscillator
- SNTI 0.00
- NYC 27.50
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.